Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting a study titled ‘Real World Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy Against RSV Illness in Infants.’ The study aims to evaluate the effectiveness of the ABRYSVO vaccine administered during pregnancy in preventing RSV-related illnesses in infants. This research is significant as it assesses the vaccine’s impact in real-world settings across multiple seasons in Argentina and Uruguay.
The intervention being tested is ABRYSVO, a bivalent RSV prefusion F protein-based vaccine designed to protect against both RSV-A and RSV-B. The vaccine is intended to reduce RSV-associated outcomes in infants when administered to pregnant individuals.
The study is observational with a case-control model and a retrospective time perspective. It employs three design approaches: a test negative design, a descriptive cohort design, and an ecologic before-and-after design. These methods aim to evaluate vaccine effectiveness, describe clinical features of hospitalized infants, and assess the impact of the vaccination program.
The study began on August 26, 2024, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
This study could have significant market implications for Pfizer, potentially boosting investor confidence and stock performance if the vaccine demonstrates effectiveness. It also positions Pfizer competitively in the RSV vaccine market, highlighting its commitment to addressing respiratory illnesses in infants.
The study is ongoing, with further details available on the ClinicalTrials portal.